Neurobiology of Opioid Dependence: 3 - 3

This study has been completed.

First Received: September 20, 1999 Last Updated: June 23, 2005 History of Changes

Sponsor:	National Institute on Drug Abuse (NIDA)
Collaborator:	Yale University
Information provided by:	National Institute on Drug Abuse (NIDA)
ClinicalTrials.gov Identifier:	NCT00000194

Purpose

The purpose of this study is to study the effects of cycloserine on naloxone-precipitated opiate withdrawal.

Condition	Intervention	Phase
Opioid-Related Disorders	Drug: Cycloserine	Phase II

Study Type:	Interventional
Study Design:	Treatment, Double-Blind, Placebo Control
Official Title:	Neurobiology of Opioid Dependence: 3

Resource links provided by NLM:

Drug Information available for: Cycloserine

U.S. FDA Resources

Further study details as provided by National Institute on Drug Abuse (NIDA):

Primary Outcome Measures:

Behavioral, subjective, measures of naloxone-preci
Phsyiological, neuroendocrine measures of naloxone

Estimated Enrollment:	0
Study Start Date:	October 1996

Eligibility

Genders Eligible for Study:	Male
Accepts Healthy Volunteers:	No

Criteria

Please contact site for information.

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00000194

Locations

United States, Connecticut
VA Connecticut Healthcare System
New Haven, Connecticut, United States, 06519

Sponsors and Collaborators

National Institute on Drug Abuse (NIDA)

Yale University

Investigators

Principal Investigator:

Marc I Rosen, M.D.

VA Connecticut Healthcare System

More Information

No publications provided

Study ID Numbers:	NIDA-00191-3, K20-00191-3
Study First Received:	September 20, 1999
Last Updated:	June 23, 2005
ClinicalTrials.gov Identifier:	NCT00000194 History of Changes
Health Authority:	United States: Federal Government

Additional relevant MeSH terms:

Antimetabolites
Cycloserine
Anti-Infective Agents
Molecular Mechanisms of Pharmacological Action
Disorders of Environmental Origin
Anti-Infective Agents, Urinary
Opioid-Related Disorders
Renal Agents

Pharmacologic Actions
Antibiotics, Antitubercular
Anti-Bacterial Agents
Mental Disorders
Therapeutic Uses
Substance-Related Disorders
Antitubercular Agents

ClinicalTrials.gov processed this record on November 09, 2009